CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 91 enrolled
Drug / intervention
BI 695502 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01608087
NCT01608087Phase 1Completed
CompareCT.gov

Pharmacokinetics and Safety of BI 695502 in Healthy Subjects: a Randomized, Single-blind, Single-dose, Parallel-arm, Active-comparator Clinical Phase I Study

Boehringer Ingelheim·interventional·Posted May 30, 2012·Updated Nov 8, 2019

In Brief

A Phase 1 clinical trial evaluating BI 695502 and bevacizumab for Healthy. Completed, enrolled 91 participants across 2 sites.

Detailed Summary

This trial will investigate the pharmacokinetics and safety of BI 695502 and to establish pharmacokinetic biosimilarity of BI 695502 compared to bevacizumab.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesNew Zealand
Collaborators--

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 30, 2012
Enrollment StartMay 1, 2012
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 14.1 years ago

Interventions

BI 695502drug

BI 695502 single i.v. infusion

bevacizumabdrug

bevacizumab single i.v. infusion

bevacizumabdrug

bevacizumab single i.v. infusion